What is iCleanse?
iCleanse operates at the nexus of health-tech and digital out-of-home (DOOH) advertising. Its core product, the Swift UV unit, provides rapid, 15-second disinfection for mobile devices and high-touch equipment, currently utilized in over 100 U.S. hospitals. Beyond its primary function as a sanitation tool, the hardware features a 10-inch high-resolution LCD display. This design choice transforms a standard hygiene station into a sophisticated advertising medium, allowing businesses to monetize the dwell time of users while simultaneously promoting public health. By addressing the critical need for infection control in public spaces, iCleanse has carved out a unique market position that bridges the gap between essential facility management and modern digital engagement strategies.
How much funding has iCleanse raised?
iCleanse has raised a total of $2.5M across 2 funding rounds:
Debt
$1.5M
Debt
$1M
Debt (2022): $1.5M with participation from Enhanced Capital
Debt (2023): $1M led by Enhanced Capital
Key Investors in iCleanse
Enhanced Capital
Enhanced Capital is a diversified national asset management firm that provides investment capital to small businesses underserved by traditional financing sources. The company focuses on strategies such as project finance, sustainable infrastructure, and real estate, aiming to unlock private sector resources aligned with public policy goals.
What's next for iCleanse?
With the recent capital infusion, iCleanse is poised to expand its market penetration beyond the healthcare sector into broader commercial landscapes, including transit hubs, corporate offices, and retail environments. The strategic focus will likely center on optimizing the advertising network integrated into its hardware, potentially scaling its digital content delivery capabilities to attract premium brand partnerships. As the company matures, the integration of data analytics regarding unit usage and audience engagement will be pivotal in refining its value proposition to advertisers. Furthermore, the firm is expected to continue its focus on operational efficiency, ensuring that its UV-C technology remains the gold standard for rapid, effective surface disinfection in high-traffic, enterprise-level settings.
See full iCleanse company page
